



Educational Workshop

September 15-16, 2018 | Marriott Tampa Waterside Hotel | Tampa, FL USA

PROGRAM CO-CHAIRS:



Kenneth Shain, MD, PhD
Moffitt Cancer Center



Ravi Vij, MD, MBA
Washington University

PLANNING COMMITTEE:

Nikhil C Munshi, MD
Dana Farber Cancer Institute,
Boston

Noopur Raje, MD
Massachusetts General Hospital

Shaji Kumar, MD
Mayo Clinic

Join us for an educational workshop on the diagnosis, treatment and monitoring of plasma cell malignancies, including current practices and opportunities for improvement.

The workshop will include lectures plus roundtable discussions around the most hot and controversial topics, featuring point-counterpoint conversations between invited speakers and local hematologists based on both challenging questions and clinical cases.

Numerous networking opportunities will also be available in order to establish potential collaborations among speakers and participants.

In support of improving patient care, this activity has been planned and implemented by Mayo Clinic College of Medicine and Science and International Myeloma Society. Mayo Clinic College of Medicine and Science is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



JOINT ACCREDITATION[®]
INTERPROFESSIONAL CONTINUING EDUCATION

The Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 11.50 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is supported by an educational grant from Sanofi Genzyme.

FEATURED SPEAKERS:

SATURDAY

Multiple Myeloma: A journey through decades

Robert A. Kyle, MD
Mayo Clinic
Rochester, MN



SUNDAY

The future of therapy in myeloma?

Kenneth C. Anderson, MD
Dana-Farber Cancer Institute
Boston, MA



TAMPA PRELIMINARY PROGRAM

Saturday, September 15, 2018

- 08:15-08:30 **Welcome and introduction**
- 08:30-9:00 **Multiple Myeloma: A journey through decades**
Robert Kyle, MD
- 9:00-9:30 **Multiple Myeloma: Novel Biologic Insights**
Nikhil Munshi, MD
- 9:30-10:00 **Tracking Genetic Heterogeneity**
Jens Lohr, MD
- 10:00-10:30 **Coffee Break**
- 10:30-11:00 **Implementing appropriate tests for follow up and treatment decisions: serum markers and imaging**
Ajay Nooka, MD
- 11:00-11:30 **Minimal residual Disease. How and when to do it?**
Phil McCarthy, MD
- 11:30-12:00 **Roundtable: How to do a correct diagnosis and follow-up: Controversial cases with emphasis on local practice**
Moderator: Nikhil Munshi, MD
Discussants: Jens Lohr, MD, , Ajay Nooka, MD, Phil McCarthy, MD, Kenneth Shain, MD
- 12:00-13:00 **Lunch**
- 13:00-13:30 **MGUS & Smoldering Myeloma: Risk Stratification and Therapeutic Options**
Natalie Callander, MD
- 13:30-15:30 **How I treat newly diagnosed transplant eligible MM patients?**
- 13:30-13:50 **The best induction and risk adapted approaches for initial therapy in myeloma**
Ravi Vij, MD
- 13:50-14:10 **Role of autologous stem cell transplant**
Hari Parameswaran, MD
- 14:10-14:30 **Role of consolidation and maintenance?**
Sundar Jagannath, MD
- 14:30-14:50 **Allogeneic stem cell transplant in myeloma: is there still a role?**
Sergio Giral, MD
- 14:50-15:30 **Roundtable: Optimizing the use of stem cell transplant in myeloma Controversial cases presented by local physicians with emphasis on local practice**
Moderator: Sundar Jagannath, MD
Discussants: Sundar Jagannath, MD, Sergio Giral, MD, Hari Parameswaran, MD, Kenneth Anderson, MD, Melissa Alsina, MD
- 15:30-16:00 **Coffee Break**
- 16:00-16:30 **Management of Renal Disease in monoclonal gammopathies**
Nelson Leung, MD
- 16:30-17:00 **Management of Bone disease and other supportive care Strategies**
Matthew Drake, MD

TAMPA PRELIMINARY PROGRAM CONTINUED

Sunday, September 16, 2018

- 8:00-8:30 **The future of therapy in myeloma?**
Kenneth Anderson, MD
- 8:30-9:40 **How I treat newly diagnosed elderly patients?**
- 8:30-8:50 **What is the ideal initial therapy for the older patient?**
Elizabeth O'Donnell, MD
- 8:50-9:10 **How should we adapt therapy for the elderly?**
Ravi Vij, MD
- 9:10-9:40 **Roundtable: Controversial elderly cases with emphasis on US practice**
Moderator: Melissa Alsina, MD
Discussants: Ravi Vij, MD, Jacob Laubach, MD, Elizabeth O'Donnell, MD, Nikhil Munshi, MD, Sundar Jagannath, MD
- 9:40-10:10 **Coffee Break**
- 10:10-11:30 **How to make the right choices in the relapsed patient?**
- 10:10-10:30 **How do we manage early relapse**
Sagar Lonial, MD
- 10:30-10:50 **Approaches for refractory relapsed myeloma**
Robert Orlowski, MD
- 10:50-11:30 **Roundtable: Controversial cases with emphasis on US practice**
Moderator: Sagar Lonial, MD
Discussants: Ravi Vij, MD, Sundar Jagannath, MD, Robert Orlowski, MD, Phil McCarthy, MD
- 11:30-12:00 **Amyloidosis: "Under-diagnosed disorder"**
Suzanne Lentsch, MD
- 12:00-12:30 **Waldenström Macroglobulinemia**
Jorge Castillo, MD
- 12.30-13:00 **Immunotherapy including CAR T cells**
Adam Cohen, MD
- 13:00-13:30 **Novel Drug Targets in Clinical Trials**
Andrew Yee, MD

THANK YOU TO OUR SPONSORS

Gold



Silver



Additional Support Provided By

